Cambridge Healthtech Institute初開催
Targeting Transcription Factors
PLENARY KEYNOTE PROGRAM
Plenary Keynote Introduction (Sponsorship Opportunity Available)10:45 am
PLENARY: The New Science of Therapeutics
Jay E. Bradner, MD, Physician Scientist, Former President, Novartis Institutes for BioMedical Research, Inc.
I will share reflections on how new paradigms in the science of therapeutics are creating opportunities to approach historic challenges in medicine. Specifically, I will share approaches to targeting transcription factors and discuss how modularity is a paradigm for next-generation low-molecular weight and biological therapeutics. Finally, I will offer reflections on drug development and the fitness, opportunities, and challenges of the biomedical ecosystem.
PLENARY: Accelerating Drug Discovery Using Machine Learning and Cell Painting Images
Microscopy images can reveal whether a cell is diseased, is responding to a drug treatment, or whether a pathway has been disrupted by a genetic mutation. In a strategy called image-based profiling, often using the Cell Painting assay, we extract hundreds of features of cells from images. Just like transcriptional profiling, the similarities and differences in the patterns of extracted features reveal connections among diseases, drugs, and genes.
Enjoy Lunch on Your Own12:25 pm
Welcome Remarks1:45 pm
TRANSCRIPTION FACTOR-DRIVEN TARGETED THERAPIES
Profiling the DNA Regulome to Discover Direct Inhibitors of the Brachyury Transcription Factor
Alexander Federation, PhD, CoFounder & CEO, Talus Bioscience
TF-Scan is a live-cell assay that reports the proteome-wide changes in protein:DNA binding activity in response to small molecule perturbations. Using this technology, we discovered covalent compounds capable of binding and disrupting the activity of brachyury, a previously undruggable TF that drives sarcoma. Hit validation and medicinal chemistry led to a covalent chemical probe for brachyury, effective in chordoma cell line models with in vivo activity against patient-derived xenografts.
Mammalian SWI/SNF Chromatin Remodeling Complex- Transcription Factor Interactions in Human Cancer
Cigall Kadoch, PhD, Associate Professor, Pediatric Oncology, Dana-Farber Cancer Institute/Harvard Medical School; Scientific Founder, Foghorn Therapeutics
ATP-dependent chromatin remodeling complexes are heterogeneous, multi-component molecular machines that govern genomic accessibility and gene expression and are frequently perturbed in human disease. This presentation highlights biochemical and structural advances that have enabled the mechanistic understanding of mSWI/SNF complex activities and functional assignment of mSWI/SNF-transcription factor interactions in developmental and disease states, opening new opportunities for targeted intervention.
Daniela Crespi, PhD, Principal Investigator Proposal, Biological Sciences Department, Axxam
Transcription factors represent key biological players in multiple signaling pathways within eukaryotic cells. It is therefore not surprising that their dysregulation contributes to the pathogenesis of a plethora of human diseases, including cancer, making them highly attractive for therapeutic intervention. Axxam has developed several cell-free and cell-based assays for therapeutically relevant transcription factors, such as c-myc and TEAD1, aiming at finding meaningful modulators that can be further developed into lead candidates.
Refreshment Break in the Exhibit Hall with Poster Viewing3:25 pm
A Transcription Factor Atlas of Directed Differentiation
Julia Joung, PhD, Postdoctoral Fellow, Laboratory of Dr. Jonathan Weissman, Whitehead Institute
To comprehensively understand transcription factors (TFs), we created a barcoded library of all human TF splice isoforms and applied it to build a TF Atlas charting single-cell expression profiles of pluripotent stem cells overexpressing each TF. We validated TFs for generation of diverse cell types, spanning all three germ layers and trophoblasts. We further developed a strategy for predicting TF combinations that produce target cell types to accelerate cellular engineering.
Synthetic Transcription-Factor Activity Responsive (STAR) Gene Circuits for Cancer Immunotherapy
Ming-Ru Wu, MD, PhD, Assistant Professor, Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School
We have developed synthetic cancer-targeting gene circuits that specifically target cancer cells. Once the circuits enter cells, they will sense the activity of several cancer-associated transcription factors and get activated in tumor cells to trigger tumor-localized combinatorial immunotherapy. Circuits mediate robust therapeutic efficacy in ovarian cancer mouse models. This platform can be adjusted to treat multiple cancer types and can potentially trigger genetically encodable immunomodulators as therapeutic outputs.
Dinner Short Course Registration*5:00 pm
*Premium Pricing or separate registration required. See Short Courses page for details.
Close of Day8:00 pm
Registration and Morning Coffee7:30 am
TRANSCRIPTION FACTORS AS DRUG TARGETS
Targeting CBP/p300 - Inhibition vs. Degradation for Potent Anti-Tumor Efficacy
Murali Ramachandra, PhD, CEO, Aurigene Discovery Technologies Ltd.
E1A binding protein (p300) and its paralog CREB binding protein (CBP or CREBBP) are key transcriptional co-activators that play a critical role in gene expression in both tumor and immune cells. Our efforts in understanding the distinct advantages of inhibition vs. degradation of CBP/p300 for use in cancer therapy resulting from a combination of synthetic lethality, inhibition of pro-tumorigenic signaling, and activation of anti-tumor immune response will be presented.
Targeting MYC Through WDR5
William Tansey, PhD, Ingram Professor of Cancer Research, Professor of Cell & Development Biology, Vanderbilt University
MYC proteins are highly validated but challenging targets for cancer therapy. In this talk, I will describe our efforts-in collaboration with Dr. Stephen Fesik-to target MYC via its chromatin cofactor WDR5. These efforts, now nearing completion, have generated highly potent, orally bioavailable, and safe drug-like WDR5 inhibitors that stymie the ability of MYC to promote protein synthesis and display anti-tumor activity in multiple MYC-driven cancer models.
Small-Molecule Cyanamide Pan-TEAD YAP1 Covalent Antagonists
Samy O. Meroueh, PhD, Associate Professor, Biochemistry & Molecular Biology, Indiana University
TEADs transcription factors bind to co-activators YAP1 or TAZ to promote tumor growth and metastasis. We report isoindoline and octahydroisoindole small molecules with a cyanamide electrophile that form a covalent complex with a cysteine in the TEAD palmitate cavity. Compounds inhibited YAP1 binding to TEADs and cocrystal structures revealed their binding mode. Compounds inhibited TEAD1-4 transcriptional activity in mammalian cells. Several compounds inhibited cell viability in several cancer cell lines.
FEATURED PRESENTATION: Elucidating the MOA of Allosteric Lipid Pocket Inhibitors of TEAD
Debra Brennan, Executive Director, Medicinal Chemistry, Nimbus Therapeutics
At Nimbus, we have overcome the challenges of TEAD’s central lipid pocket to develop a robust biochemical assay and have used structural elucidation and computational chemistry, along with in-parallel orthogonal approaches to understand the mechanism-of-action (MOA) of small molecule inhibitors of TEADs. Our work uncovers different MOAs of TEAD small molecule inhibitors and provides hypotheses for these MOAs which could help the discovery of more potent and selective inhibitors.
In-Person Group Discussions10:05 am
Coffee Break in the Exhibit Hall with Poster Viewing10:50 am
HT-CETSA for Transcription Factor Ligand Discovery
Rhushikesh Kulkarni, PhD, Principal Scientist, Oncology Chemical Biology, Pfizer Inc.
High-throughput CETSA (HT-CETSA) is a promising screening strategy for identifying target binders in the native cellular environment. We have performed HT-CETSA screening to enable chemical engagement of transcription factors. Here we will discuss key learnings from our HT-CETSA screening efforts.
A Degrader of BTK and IKZF
Mark Noviski, PhD, Principal Scientist, Discovery Biology, Nurix Therapeutics, Inc.
I describe preclinical and clinical data for NX2127, a degrader of Bruton Tyrosine Kinase (BTK), a master regulator of B cells and implicated in cancer. We developed two unique and functionally distinct BTK degraders that harness cereblon (CRBN), an E3 ligase active in hematopoietic cells. I describe the BTK degrader that also has the ability to induce degradation of neosubstrates Ikaros (IKZF1) and Aiolos (IKZF3).
Sponsored Presentation (Opportunity Available)12:30 pm
Transition to Lunch1:00 pm
Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own1:05 pm
Dessert Break in the Exhibit Hall with Last Chance for Poster Viewing1:35 pm
DEGRADING ONCOGENIC TRANSCRIPTION FACTORS
Understanding the Recruitment of Zinc-Finger-Based Transcription Factors to Cereblon in the Presence of Molecular Glues
Charles Wartchow, PhD, Associate Director, Global Discovery Chemistry, Novartis Institutes for BioMedical Research
Transcription factors are known to bind to cereblon in the presence of molecular glues and some reports implicate interactions with multiple zinc fingers. We present biophysical and structural assessments of the minimal binding domains of IKZF2 and another transcription factor revealing that two zinc fingers interact with cereblon:glue complexes. In these examples, the binding modes are distinct and may have implications for the design of selective degraders.
Discovery and Characterization of an IKZF2 Selective Molecular Glue Degrader with Best-in-Class Potential
Helai Mohammad, PhD, Vice President & Head, Biology, Proteovant Therapeutics
IKZF2 (Helios) plays an important role in maintaining stability and function of regulatory T cells (Tregs). Proteovant applied a structure-guided drug discovery approach to identify an IKZF2 selective molecular glue degrader, PVTX-405. PVTX-405 shows selective degradation of IKZF2 in vitro and in vivo. PVTX-405 treatment reduces suppressive activity of human Treg cells ex vivo and delays growth of MC38 tumors in immune competent mice in vivo.
New Technologies for Advancing the Targeted Protein Degradation
H. umit Kaniskan, PhD, Associate Professor, Laboratory of Dr. Jian Jin, Department of Pharmacological Sciences, Icahn School of Medicine at Mt. Sinai
The Jian Jin Laboratory at Mount Sinai is a leader in discovering novel degraders targeting oncogenic proteins and developing new technologies for advancing the targeted protein degradation field. Our lab’s recent progress advancing the targeted protein degradation, including TF-PROTAC, Bridged PROTAC, Folate-caged PROTAC, opto-PROTAC, and KEAP1-recruiting PROTAC technologies will be presented.
Targeted Degradation of STAT Proteins
Longchuan Bai, PhD, Associate Research Scientist, Laboratory of Dr. Shaomeng Wang, University of Michigan
STAT (signal transducer and activator of transcription) proteins are a family of transcription factors that mediate signal transduction downstream of cytokine and growth factor receptors. Hyperactivation of STAT3 and STAT5 has been linked to cancer cell proliferation, survival, stemness, and immune evasion, making them attractive targets for cancer therapy. STATs have been difficult to target by traditional small-molecule inhibitors. Employing the PROTAC technology, we have developed highly selective and potent STAT3 or STAT5 degraders with strong anti-tumor activities in hematologic cancer models.
Close of Conference4:20 pm